JP2022512450A - Gpc3を標的とする免疫エフェクター細胞およびその応用 - Google Patents
Gpc3を標的とする免疫エフェクター細胞およびその応用 Download PDFInfo
- Publication number
- JP2022512450A JP2022512450A JP2021534233A JP2021534233A JP2022512450A JP 2022512450 A JP2022512450 A JP 2022512450A JP 2021534233 A JP2021534233 A JP 2021534233A JP 2021534233 A JP2021534233 A JP 2021534233A JP 2022512450 A JP2022512450 A JP 2022512450A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune response
- cell
- gpc3
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100032530 Glypican-3 Human genes 0.000 title claims abstract description 29
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 title claims abstract description 29
- 229940121354 immunomodulator Drugs 0.000 title claims description 11
- 239000012642 immune effector Substances 0.000 title claims description 10
- 230000008685 targeting Effects 0.000 title abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 380
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 89
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 77
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 66
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 66
- 230000028993 immune response Effects 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 89
- 230000027455 binding Effects 0.000 claims description 80
- 239000000427 antigen Substances 0.000 claims description 77
- 108091007433 antigens Proteins 0.000 claims description 77
- 102000036639 antigens Human genes 0.000 claims description 77
- 102000005962 receptors Human genes 0.000 claims description 56
- 108020003175 receptors Proteins 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 38
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 31
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 31
- 230000003834 intracellular effect Effects 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 21
- 239000003446 ligand Substances 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 11
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 10
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 10
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 210000004698 lymphocyte Anatomy 0.000 claims description 10
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 239000011886 peripheral blood Substances 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 10
- 102100027207 CD27 antigen Human genes 0.000 claims description 9
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000011664 signaling Effects 0.000 claims description 9
- -1 ICOS Proteins 0.000 claims description 8
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 6
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 6
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 6
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 210000000822 natural killer cell Anatomy 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 102100024263 CD160 antigen Human genes 0.000 claims description 5
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 5
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 5
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 5
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 5
- 230000000139 costimulatory effect Effects 0.000 claims description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100038077 CD226 antigen Human genes 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100035793 CD83 antigen Human genes 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 4
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims description 4
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 4
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims description 4
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 4
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 4
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims description 4
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 4
- 102100039904 Integrin alpha-D Human genes 0.000 claims description 4
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 4
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 4
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 4
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 4
- 102000014128 RANK Ligand Human genes 0.000 claims description 4
- 108010025832 RANK Ligand Proteins 0.000 claims description 4
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 3
- 101710145634 Antigen 1 Proteins 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 102100038078 CD276 antigen Human genes 0.000 claims description 3
- 101710185679 CD276 antigen Proteins 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 3
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims description 3
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims description 3
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 3
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 3
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 3
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 3
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 230000020411 cell activation Effects 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 3
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 108010056102 CD100 antigen Proteins 0.000 claims description 2
- 108010017009 CD11b Antigen Proteins 0.000 claims description 2
- 108010062802 CD66 antigens Proteins 0.000 claims description 2
- 102100027217 CD82 antigen Human genes 0.000 claims description 2
- 101710139831 CD82 antigen Proteins 0.000 claims description 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 2
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims description 2
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims description 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 2
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 2
- 108010041100 Integrin alpha6 Proteins 0.000 claims description 2
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims description 2
- 102100033016 Integrin beta-7 Human genes 0.000 claims description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 2
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 2
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 2
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 2
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 2
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 2
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 230000009278 visceral effect Effects 0.000 claims description 2
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 16
- 238000000338 in vitro Methods 0.000 abstract description 9
- 230000002147 killing effect Effects 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 5
- 229940117681 interleukin-12 Drugs 0.000 description 50
- 108700019146 Transgenes Proteins 0.000 description 38
- 150000007523 nucleic acids Chemical class 0.000 description 32
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 241000700605 Viruses Species 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 238000001994 activation Methods 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 239000012636 effector Substances 0.000 description 14
- 230000028327 secretion Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 241000713666 Lentivirus Species 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 230000006044 T cell activation Effects 0.000 description 11
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 241001430294 unidentified retrovirus Species 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 230000004068 intracellular signaling Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 101001034843 Mus musculus Interferon-induced transmembrane protein 1 Proteins 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 108010056030 retronectin Proteins 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102000004631 Calcineurin Human genes 0.000 description 3
- 108010042955 Calcineurin Proteins 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 108010092694 L-Selectin Proteins 0.000 description 3
- 102000016551 L-selectin Human genes 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 101710156660 T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000002617 apheresis Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 102000002627 4-1BB Ligand Human genes 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 2
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 2
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 2
- 101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 description 2
- 102100034398 Nuclear factor of activated T-cells, cytoplasmic 4 Human genes 0.000 description 2
- 101710151215 Nuclear factor of activated T-cells, cytoplasmic 4 Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000028956 calcium-mediated signaling Effects 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 230000001875 tumorinhibitory effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ILFPCMXTASDZKM-YFKPBYRVSA-N (1s)-2-methylidene-3-oxocyclopentane-1-carboxylic acid Chemical compound OC(=O)[C@H]1CCC(=O)C1=C ILFPCMXTASDZKM-YFKPBYRVSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- PCZUSAVLHNFWAD-UHFFFAOYSA-N 2-sulfanylidene-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound NP1(=S)NCCCN1 PCZUSAVLHNFWAD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 101100007857 Bacillus subtilis (strain 168) cspB gene Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000713686 Bovine lentivirus group Species 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 101100137785 Escherichia coli (strain K12) proX gene Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 101100276041 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) ctpD gene Proteins 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102100034400 Nuclear factor of activated T-cells, cytoplasmic 2 Human genes 0.000 description 1
- 101710151538 Nuclear factor of activated T-cells, cytoplasmic 2 Proteins 0.000 description 1
- 102100034399 Nuclear factor of activated T-cells, cytoplasmic 3 Human genes 0.000 description 1
- 101710151545 Nuclear factor of activated T-cells, cytoplasmic 3 Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108030003690 Phosphatidylinositol-4,5-bisphosphate 3-kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000454 anti-cipatory effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 101150008667 cadA gene Proteins 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 101150110403 cspA gene Proteins 0.000 description 1
- 101150068339 cspLA gene Proteins 0.000 description 1
- 101150037603 cst-1 gene Proteins 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940045681 other alkylating agent in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- ILFPCMXTASDZKM-UHFFFAOYSA-N sarkomycin Natural products OC(=O)C1CCC(=O)C1=C ILFPCMXTASDZKM-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本発明の第1の態様に記載の免疫応答細胞、および
薬学的に許容されるベクターまたは賦形剤を含む。
第5の態様において、本発明は、
本発明第1の態様に記載の免疫応答細胞、および
前記免疫応答細胞を個体に投与する方法を指導する取扱説明書を含むキットを提供する。
本明細書で使用される「活性化」および「アクティブ化」という用語は、交換可能に使用され、それたおよび他の文法形態は、細胞が休止状態から活性状態に変化する過程を指すことができる。当該過程は、抗原、遊走および/または機能的活性状態の表現型または遺伝的変化に対応する応答を含む。例えば、「活性化」という用語は、T細胞の段階的な活性化過程を指すことができる。例えば、T細胞は、完全に活性化するために少なくとも二つのシグナルを必要とする可能性がある。第1のシグナルは、TCRが抗原-MHC複合体によって結合された後に発生る可能性があり、第2のシグナルは、共刺激分子(表3にリストされた共刺激分子を参照)の結合によって発生する可能性がある。インビトロにおいて、抗CD3は、前記第1のシグナルをシミュレートすることができ、抗CD28は、前記第2のシグナルをシミュレートすることができる。例えば、操作されたT細胞は、発現されたCARによって活性化されることができる。本明細書で使用されるT細胞活性化またはT細胞トリガーは、検出可能な細胞増殖、サイトカイン生成および/または検出可能なエフェクター機能を誘導するために十分に刺激されたT細胞の状態を指すことができる。
いくつかの実施形態において、本発明は、免疫応答細胞を提供し、当該細胞は、GPC3に特異的に結合する受容体および外因性IL12を発現する。
標的結合抗原受容体またはCARをコードする導入遺伝子を細胞に組み込むことができる。例えば、導入遺伝子を、T細胞等の免疫応答細胞に組み込むことができる。細胞に挿入されると、導入遺伝子は、メッセンジャーRNA(mRNA)のコピーである相補DNA(cDNA)フラグメント、またはそのゲノムDNAの元の領域にある遺伝子自体(イントロンの有無にかからわず)であり得る。
本明細書で使用される「誘導型プロモーター」という用語は、制御されたプロモーターであり、期待される条件が達成される前に操作可能に連結された遺伝子を発現または低発現し、期待される条件が満たされると、その操作可能に連結される遺伝子を発現または高発現することを指す。例えば、いくつかの実施形態において、本発明の誘導型プロモーターは、細胞内の正常または高酸素含有量の条件下で作動可能に連結された遺伝子を発現または低発現しなく、細胞内の酸素含有量の減少に応答して、低酸素条件下または高酸素含有量化でそれに動作可能に連結された遺伝子を発現または高発現する。いくつかの実施形態において、本明細書で使用される誘導型プロモーターは、低酸素誘導性転写因子-1α(Hypoxia-Inducible Transcription factor-1α、HIF-1α)を含む。いくつかの実施形態において、本明細書で使用される「誘導型プロモーター」という用語は、免疫応答細胞が抗原に接触する前、または免疫応答細胞が活性化されない場合、操作可能に連結される遺伝子を発現または低発現し、免疫応答細胞が抗原に接触するか、または免疫応答細胞が活性化される場合にのみ、それらに操作可能に連結される遺伝子と高レベル発現するか、または低酸素条件下での発現を促進する「免疫細胞誘導型プロモーター」を指す。いくつかの実施形態において、前記「免疫細胞誘導型プロモーター」は、NFAT(活性化T細胞核因子)型プロモーターを含む。
前記抗原結合受容体をコードする導入遺伝子で細胞をトランスフェクトすることができる。導入遺伝子の濃度は、約100ピコグラム~約50マイクログラムであり得る。いくつかの状況において、細胞に導入された核酸(例えば、ssDNA、dsDNAまたはRNA)の量を変更して、トランスフェクション効率および/または細胞生存率を最適化することができる。例えば、エレクトロポレーションのために1マイクログラムのdsDNAを各細胞サンプルに加えることができる。いくつかの状況において、最適なトランスフェクション効率および/または細胞生存率に必要な核酸(例えば、二本鎖DNA)の量は、細胞の種類によって異なる。いくつかの状況において、各サンプルに使用される核酸(例えば、dsDNA)の量は、トランスフェクション効率および/または細胞生存率に直接対応されることができる。例えば、一連のトランスフェクション濃度。ベクターによってコードされる導入遺伝子は、細胞ゲノムに統合されることができる。いくつかの状況において、ベクターによってコードされる導入遺伝子は、前方に統合される。他の状況において、ベクターによってコードされる導入遺伝子は、逆方向で統合される。
本発明の免疫応答細胞は、医薬組成物の調製に適用することができる。有効量の免疫応答細胞を含むことに加えて、前記医薬組成物は、薬学的に許容されるベクターをさらに含むことができる。「薬学的に許容される」という用語は、分子実体および組成物が動物またはヒトに適切に投与された場合、それらが有害、アレルギーまたは他の副作用を引き起こさないことを指す。
いくつかの実施形態において、本発明の免疫応答細胞は、別の治療剤と組み合わせて投与することができる。いくつかの実施形態において、前記別の治療剤は、化学療法薬である。本発明の免疫応答細胞と組み合わせて応用されることができる化学療法薬は、ビンクリスチン、ビンブラスチン、ビンデシン和ノビビン(TM)(ビノレルビン、5’-硫化脱水素)を含む有糸分裂阻害剤(ビンブラスチンアルカロイド)、CamptosarTM(イリノテカンHCL)、HycamtinTM(トポテカンHCL)およびカンプトテシンとその類似体に由来する他の化合物を含むカンプトテシン化合物等のトポイソメラーゼI阻害剤、エトポシド、テニポシドおよびミドキシゾズ等のポドフィロトキシン誘導体、シスプラチン、シクロホスファミド、ナイトロジェンマスタード、トリメチレンチオホスホルアミド、カルムスチン、ブスルファン、クロラムブシル、ブリキアジン、ウラシルマスタード、クロプロフェンおよびダカルバジン等のアルキル化剤、シタラビン、フルオロウラシル、メトトレキサート、メルカプトプリン、アザチオプリンおよびプロカルバジンを含む代謝拮抗剤、ドキソルビシン、ブレオマイシン、ダクチノマイシン、ダウノルビシン、マイシノマイシン、マイトマイシン、サルコマイシンCおよびダウノルビシン等を含むがこれらに限定されない、抗生物質、ならびに抗腫瘍抗体、ダカルバジン、アザシチジン、アムサカム、メルファラン、イホスファミドおよびミトキサントロン等を含むがこれらに限定されない、他の化学療法薬を含むが、これらに限定されない。
本発明は、本発明の免疫応答細胞を含むキットをさらに提供する。前記キットは、癌、病原体感染、免疫障害または同種異系移植を治療または予防するために使用されることができる。一実施形態において、キットは、一つまたは複数の単位剤形を含む有効量の免疫応答細胞を含む治療的または予防的組成物を含むことができる。
1.プラスミドの構築
本実施例で使用されるキメラ抗原受容体は、第2世代のキメラ抗原受容体であり、使用されるGPC3受容体の細胞外ドメインを標的とするscFvのヌクレオチドコード配列は、SEQ ID NO:1に示され、CD28の膜貫通ドメイン、CD28の細胞内ドメイン、およびCD3ζをさらに有する。図1Aに示されるように、GPC3-CAR-T細胞およびIL12-GPC3-CAR T細胞のプラスミドを構築し、具体的には、次のとおりである。
a.レンチウイルスのパッケージング
1)6~10継代まで培養した293T細胞をペトリ皿に5×106の密度で接種し、37℃、5%CO2で一晩培養し、培地は、10%ウシ胎児血清(Gibico)を含むDMEMであり、
2)5.4μgの標的遺伝子プラスミドGPC3-CAR-TおよびIL12-GPC3-CAR Tと6.2μgのパッケージングプラスミドpRsv-REV、6.2μgのRRE-PMDLg、2.4μgのVsvgとを800μLのブランクDMEM培養液に溶解し、混合して、プラスミド混合液を得、
3)60μgのPEI(1μg/μl)を800μlの無血清DMEM培養液に溶解し、室温下で5分間インキュベートして、PEI混合液を得、
4)プラスミド混合液をPEI混合液に加えて均等に混合し、室温下で20分間インキュベートして、トランスフェクション複合体を形成し、
5)11mlのDMEM培地を含む10cmのペトリ皿に1.6mlのトランスフェクション複合体を滴下し、4~5時間後、トランスフェクトされた293T細胞を10%FBSのDMEM培基と交換し、37℃で72時間インキュベートし、ウイルス溶液の上清を収集する。
1)5XPEG8000NaClの調製:8.766gのNaClと50gのPEG8000とを秤量して200mlのMilli-Q純水に溶解し、121℃で30分間湿熱滅菌し、4℃で保存し、
2)0.45μmのフィルターを使用してウイルス上清溶液をろ過し、30mlごとにろ過した後のウイルス初期溶液に、7.5mlの5X PEG-8000NaCl母液を加え、20~30分ごとに1回、合計3~5回混合し、4℃で一晩置き、遠心分離した後上清を吸引して捨て、静止して残留液体を除去し、適切な量のレンチウイルス溶解液を加えてレンチウイルスペレットを溶解し、濃縮したウイルス懸濁液を-80℃で保存する。
GPC3-CAR-T:2.4×108U/ml
IL12-GPC3-CAR T:1×108U/mlである。
3.GPC3-CAR-T細胞、IL12-GPC3-CAR T細胞の調製
2)感染の前日、レトロネクチン(retronectin)で24ウェルプレートをコーティングし、各ウェルに380μlの5μg/mlのレトロネクチン溶液(PBS)を加え、4℃で一晩インキュベートし、
3)24ウェルプレートのレトロネクチン溶液(PBS)を捨て、1mlのPBSで2回洗浄し、レトロネクチンでコーティングした24ウェルプレートに活性化されたT細胞を接種し、各ウェルの細胞の数は、5×105であり、培養液の体積は、500μlであり、MOI=15に従って、濃縮した後のレンチウイルスをPBMC細胞に加え、32℃、1800rpmで40分間遠心分離した後、細胞インキュベーターに移し、
4)増殖培養:感染された細胞を5×105/mLの密度で1日おきに継代し、同時に、リンパ球培養液に最終濃度が500U/mLである組換えヒトIL-2を補充する。
CytoTox96非放射性細胞毒性検出キット(プロメガ会社(Promega))を使用して細胞毒性を検出し、具体的には、CytoTox96非放射性細胞毒性検出キットの取扱説明書を参照する。
1)標的細胞:Huh-7、PLC/PRF/5、SK-HEP-1細胞を標的細胞として選択し、ここで、Huh-7細胞、PLC/PRF/5細胞は、GPC3陽性であり、SK-HEP-1細胞は、GPC3陰性であり、
2)エフェクター細胞:3:1、1:1または1:3のエフェクター:ターゲット比に従って、UTD、GPC3-CAR-TおよびIL12-GPC3-CAR T細胞を加え、
実験結果は、図2に示され、UTDグループと比較して、GPC3-CAR-T/IL12-GPC3-CAR Tは、インビトロ毒性実験において、すべてより強い細胞毒性作用を示し、両者の間に有意差はない。GPC3陰性の肝臓がん細胞に対して、GPC3-CAR-T/IL12-GPC3-CAR Tは、殺傷効果の増強はない。
UTD/GPC3-CAR-T/IL12-GPC3-CAR Tを肝臓がん細胞株Huh-7、PLC/PRF/5、SK-HEP-1細胞と1:1で24時間インキュベートした後上清を収集し、ELISAで上清中のサイトカインの分泌レベルを検出する。
1.NOD/SCIDマウスにHuh-7皮下移植腫を接種
Huh-7細胞を2×106/匹で皮下接種し、腫瘍の体積は、約10日後に300mm3に達し、ランダムグループ化することにより、各グループは、6匹のマウスであり、
2.UTD/GPC3-CAR-T/IL12-GPC3-CAR T細胞を調製および増殖し、
1)皮下移植された腫瘍には、10日以内に腹腔内シクロホスファミド(100mg/kg)が注射され、
2)10日目に、NOD/SCIDマウスの移植腫瘍体積を測定しかつランダムにグループ化する。皮下移植された腫瘍マウスは、それぞれのグループには6匹のマウスがいる、UTDグループ、GPC3-CAR-TグループおよびIL12-GPC3-CAR Tグループを含む三つのグループにグループに分けられ、
3)12日目に、グループ化された後のNOD/SCIDマウス細胞に養子免疫治療を行う。1x107細胞/匹のマウスの投与量で尾静脈注射により低投与量のCAR-Tを投与し、
4)3~4日ごとにHuh-7皮下移植腫瘍の体積の大きさを測定し、マウスの各グループの腫瘍体積の変化を記録し、経時的な腫瘍体積の成長曲線を描く。結果は、図4Aおよび図4Bに示される。
免疫健全なマウスにおける自然免疫の動員におけるIL12の役割をさらに検証するために、マウス由来のCAR-Tを調製した。
マウスCD8αシグナルペプチド(SEQ ID NO:12)、抗GPC3モノクローナル抗体(SEQ ID NO:1)、マウスCD8αヒンジ領域および膜貫通領域(SEQ ID NO:13)、マウスCD28細胞内ドメイン(SEQ ID NO:14)、マウスCD3ζ細胞内ドメイン(SEQ ID NO:15)の遺伝子配列を順次に連結し、インビトロ遺伝子合成法によってGPC3-CAR-T遺伝子フラグメントを得、レトロウイルスベクターMSCV-IRES-GFPのIRES-GFPフラグメントをMlu IとSal Iとの二重酵素制限部位に置き換えて、組換えベクターMSCV-GPC3-CAR-Tを得る。マウスCAR-IL12(m-IL12-GPC3-CAR T)は、MSCV-GPC3-CAR-Tプラスミドに基づいてmNFAT6-mIL12配列を挿入し、GPC3発現する第2世代のキメラ抗原受容体およびmIL12のプラスミドMSCV-IL12-GPC3-CAR Tを構築する。mNFAT6-mIL12配列は、6*mNFAT結合モチーフ(SEQ ID NO:16)、mIL2最小プロモーター(SEQ ID NO:17)、mIL12シグナルペプチドおよびmIL12 p40(SEQ ID NO:18)、(SG4)3リンカー(SEQ ID NO:9)、mIL12 p35(SEQ ID NO:19)、PA2(SEQ ID NO:20)で構成される。
1)6~10継代まで培養した293T細胞を10cmペトリ皿に5×106の密度で接種し、37℃、5%CO2で一晩培養し、培地は、10%ウシ胎児血清(Gibico)を含むDMEMであり、
2)9μgのMSCV-GPC3-CAR-TまたはMSCV-GPC3-CAR-T-mNFAT6-mIL12と9μgのパッケージングプラスミドpCL-Ecoとを800μLの無血清DMEM培養液に溶解し、均等に混合して、プラスミド混合液を得、54μgのPEI(1μg/μl)を800μlの無血清DMEM培養液に溶解し、均等に混合し、室温下で5分間インキュベートして、PEI混合液を得、
3)プラスミド混合液をPEI混合液に加えて均等に混合し、室温下で20分間インキュベートして、トランスフェクション複合体を形成し、
4)11mlのDMEM培地を含む10cmのペトリ皿に1.6mlのトランスフェクション複合体を滴下し、4~5時間後、トランスフェクトされた293T細胞を10%FBSのDMEM培基と交換し、37℃で72時間インキュベートし、ウイルス溶液上清を収集して、mGPC3-CAR-T/mGPC3-CAR-T-mNFAT6-mIL12を保有するレトロウイルスを収集する。
健康なBalb/cマウスを取り、細胞分離キット(Cell isolation kit)(幹細胞技術(STEMCELL Technologies))を使用して、取扱説明書の記載に従って、分離してマウスの脾臓Tリンパ球を得る。
1×106のmCAR-T/mIL12-GPC3-CAR T細胞を取り、2mlの遠心分離管内に均等に二つに分け、4℃、400gで5分間遠心分離し、上清を捨て、PBSで2回洗浄する。対照グループの細胞に50μlのPE-SA(1:200で希釈する)抗体を加えて氷上で45分間インキュベートし、PBS(2%NBS)で2回洗浄し、再懸濁した後対照とし、検出グループの細胞に1:50で希釈した50μlのビオチン-ヤギ抗ヒト(biotin-Goat anti human)IgG、F(ab’)2抗体を加え、氷上で45分間インキュベートし、PBS(2%NBS)で2回洗浄し、50μlのPE-SA(1:200で希釈する)抗体を加えて氷上で45分間インキュベートする。
CytoTox96非放射性細胞毒性検出キット(プロメガ会社)を使用し、具体的には、CytoTox96非放射性細胞毒性検出キットの取扱説明書を参照する。
2)エフェクター細胞:3:1、1:1または1:3のエフェクター:ターゲット比に従って、UTD、mGPC3-m28ZおよびmGPC3-m28Z-mNFAT6-mIL12細胞を加え、
実験結果は、図10に示され、UTDグループと比較して、mGPC3-CARおよびmGPC3-m28Z-mNFAT6-mIL12(mIL12-GPC3-CAR T)は、インビトロ毒性実験において、すべてより強い細胞毒性作用を示し、両者の間に有意差はない。GPC3陰性の腫瘍細胞に対して、mGPC3-CARおよびmIL12-GPC3-CAR Tは、殺傷効果の増強はない。
UTD/mGPC3-CAR/mIL12-GPC3-CAR TをE0771-Parental、E0771-Parental-GPC3、E0771-Recurrent、E0771-Recurrent-GPC3細胞と1:1で24時間インキュベートした後上清を収集し、ELISAで上清中のサイトカインの分泌レベルを検出する。ここで、mTNF-α、mIL12、mIL2を検出するためのサンプルは、希釈する必要はなく、mIFN-γを検出するためのサンプルは、50倍に希釈される。ELISAキットは、二重抗体サンドイッチ酵素結合免疫吸着検出技術を使用する。特異的抗マウスIL-2、TNF-α、IFN-γ、IL-12モノクローナル抗体は、それぞれ高親和性ELISAプレートにプレコーティングされる。ELISAプレートのウェルに標準の試験サンプルおよびビオチン化の検出抗体を加え、インキュベートした後、サンプルに存在するmIL-2、mTNF-α、mIFN-γ、mIL-12は、それぞれ固相抗体および検出抗体に結合する。未結合物質を洗浄および除去した後、西洋ワサビペルオキシダーゼ標識ストレプトアビジン(streptavidin-HRP)を加える。洗浄した後TMBで発色する。色反応の強度は、サンプル中の上記サイトカインの濃度に正比例する。反応を停止するために停止溶液を加え、450nmの波長(参照波長570~630nm)での吸光度値を測定する。
1.C57BL/6マウスにE0771-GPC3皮下移植腫瘍を接種
E0771-GPC3細胞を1×106/匹で皮下接種し、腫瘍の体積は、約10日後に300mm3に達し、ランダムグループ化することにより、各グループは、6匹のマウスであり、
2.mUTD/mGPC3-CAR-T/mIL12-GPC3-T細胞を調製および増殖し、
3.E0771-GPC3移植腫瘍に対するmUTD/mGPC3-CAR-T/mIL12-GPC3-CAR-T細胞養子免疫治療
1)10日目に、E0771-GPC3マウスの移植腫瘍体積を測定しかつランダムにグループ化する。皮下移植腫瘍マウスは、それぞれのグループには6匹のマウスがイル、UTDグループ、mGPC3-CAR-T5×106グループ、mGPC3-CAR-T2×106グループ、mIL12-GPC3-T5×106グループ、mIL12-GPC3-T2×106グループを含む五つのグループに分けられ、
2)3~4日ごとにE0771-GPC3皮下移植腫瘍の体積の大きさを測定し、マウスの各グループの腫瘍体積の変化を記録し、経時的な腫瘍体積の成長曲線を描く。結果は、図12Aおよび図12Bに示される。
Claims (22)
- 免疫応答細胞であって、
当該細胞は、GPC3に特異的に結合する受容体および外因性IL12を発現することを特徴とする、前記免疫応答細胞。 - 前記受容体は、前記IL12に操作可能に連結されることを特徴とする
請求項1に記載の免疫応答細胞。 - 前記免疫応答細胞は、T細胞、ナチュラルキラー細胞、細胞毒性Tリンパ球、ナチュラルキラーT細胞、DNT細胞、および/または制御性T細胞を含むことを特徴とする
請求項1に記載の免疫応答細胞。 - 前記外因性IL12は、構成的発現または誘導型発現であり、
好ましくは、前記IL12を発現するために使用されるプロモーターは、免疫細胞誘導型プロモーターを含み、
好ましくは、前記免疫細胞誘導型プロモーターは、NFAT6プロモーターであることを特徴とする
請求項1に記載の免疫応答細胞。 - 前記受容体は、GPC3に特異的に結合する細胞外ドメイン、膜貫通ドメイン、および細胞内シグナルドメインを有することを特徴とする
前記請求項のいずれか1項に記載の免疫応答細胞。 - 前記受容体は、キメラ抗原受容体であり、ここで、前記細胞内ドメインは、細胞刺激シグナル分子、または細胞刺激シグナル分子と細胞活性化共刺激分子との組み合わせを含み、
好ましくは、前記細胞刺激シグナル分子は、CD3ζ、CD3γ、CD3δ、CD3ε、FcεRIγ、FcRβ、CD79a、CD79b、Fc γRIIa、DAP10、またはDAP12タンパク質の機能的シグナル伝達ドメインから選択され、より好ましくは、CD3ζであり、または
好ましくは、前記細胞活性化共刺激分子は、CD27、CD28、CD137、CD134、ICOS、OX40、CD30、CD40、PD-1、リンパ球機能関連抗原-1(LFA-1)、CD2、CD7、LIGHT、NKG2C、B7-H3、CD83に特異的に結合するリガンド、CDS、ICAM-1、GITR、BAFFR、HVEM(LIGHTR)、SLAMF7、NKp80(KLRF1)、CD160、CD19、CD4、CD8α、CD8β、IL2Rβ、IL2Rγ、IL7Rα、ITGA4、VLA1、CD49a、ITGA4、IA4、CD49D、ITGA6、VLA-6、CD49f、ITGAD、CD11d、ITGAE、CD103、ITGAL、CD11a、LFA-1、ITGAM、CD11b、ITGAX、CD11c、ITGB1、CD29、ITGB2、CD18、LFA-1、ITGB7、TNFR2、TRANCE/RANKL、DNAM1(CD226)、SLAMF4(CD244、2B4)、CD84、CD96(Tactile)、CEACAM1、CRTAM、Ly9(CD229)、CD160(BY55)、PSGL1、CD100(SEMA4D)、CD69、SLAMF6(NTB-A、Ly108)、SLAM(SLAMF1、CD150、IPO-3)、BLAME(SLAMF8)、SELPLG(CD162)、LTBR、LAT、GADS、SLP-76、PAG/Cbp、NKp44、NKp30、NKp46、およびNKG2Dのようなタンパク質機能的シグナル伝達ドメインから選択され、より好ましくは、CD27、CD28、CD137、CD134、およびICOSであることを特徴とする
請求項5に記載の免疫応答細胞。 - 前記受容体の細胞外ドメインは、SEQ ID NO:25に示されるアミノ酸配列と少なくとも90%、95%、96%、97%、98%または99%の相同性を有するアミノ酸配列を含むことを特徴とする
請求項5または6に記載の免疫応答細胞。 - 前記受容体は、SEQ ID NO:21、22、23、または24に示されるアミノ酸配列を含むか、またはSEQ ID NO:21、22、23、または24に示されるアミノ酸配列と少なくとも90%、95%、96%、97%、98%、または99%の相同性を有するアミノ酸配列を含むことを特徴とする
前記請求項のいずれか1項に記載の免疫応答細胞。 - 前記受容体および前記外因性IL12は、SEQ ID NO:28、29、30、31、32、33、34または35と少なくとも90%、95%、96%、97%、98%、または99%の相同性を有するヌクレオチド配列によってコードされ、
好ましくは、SEQ ID NO:28、29、30、または31と少なくとも90%、95%、96%、97%、98%、または99%の相同性を有するヌクレオチド配列によってコードされ、
より好ましくは、SEQ ID NO:28、29、30、または31に示されるヌクレオチド配列によってコードされることを特徴とする
請求項8に記載の免疫応答細胞。 - 前記免疫応答細胞は、外因性共刺激リガンドを含まないことを特徴とする
前記請求項のいずれか1項に記載の免疫応答細胞。 - 前記受容体および/または前記IL12は、免疫応答細胞の表面に構成的または誘導的に発現されることを特徴とする
前記請求項のいずれか1項に記載の免疫応答細胞。 - 前記免疫応答細胞は、発現構築物を含み、当該発現構築物は、前記抗原結合受容体の発現カセット、および前記IL12の発現カセットを含むことを特徴とする
前記請求項のいずれか1項に記載の免疫応答細胞。 - 前記受容体および/またはIL12は、ウイルスベクターを使用して発現し、好ましくは、前記ウイルスベクターは、レンチウイルスベクター、逆転写ウイルスベクターまたはアデノウイルスベクターを含むことを特徴とする
前記請求項のいずれか1項に記載の免疫応答細胞。 - 前記免疫応答細胞が個体に投与された後、前記個体の末梢血中のCAR-T細胞の数は、前記外因性IL12が存在しない状況に比較して少なくとも50%増加することを特徴とする
請求項1~13のいずれか1項に記載の免疫応答細胞。 - 前記免疫応答細胞が個体に投与されてから約7日後、前記個体の末梢血中のCAR-T細胞の数の合計は、6000個/μLを超え、前記免疫応答細胞が投与されてから約10日後、前記個体の末梢血中のCAR-T細胞の数の合計は、6000個/μLを超えることを特徴とする
請求項1~13のいずれか1項に記載の免疫応答細胞。 - 発現構築物であって、
当該発現構築物は、順次に連結された受容体の発現カセットおよびIL12の発現カセットを含み、ここで、前記抗原結合受容体およびIL12は、前記請求項のいずれか1項に定義されたとおりであることを特徴とする、前記発現構築物。 - 必要とする個体の腫瘍を治療するための医薬組成物の調製における請求項1~13のいずれか1項に記載の免疫応答細胞の用途。
- 前記腫瘍は、肝臓臓がん、胃がん、肺がん、乳がん、頭頚部がん、膀胱がん、卵巣がん、子宮頸がん、腎臓がん、膵臓がん、子宮頸がん、脂肪肉腫、黒色腫、副腎がん、神経鞘腫、悪性線維性組織球腫、および食道がんを含み、好ましくは、前記腫瘍は、肝臓臓がん、胃がん、肺がん、または乳がんであることを特徴とする
請求項17に記載の用途。 - 前記免疫エフェクター細胞は、腫瘍を少なくとも50%減少させることを特徴とする
請求項17または18に記載の用途。 - 前記免疫エフェクター細胞は、腫瘍を少なくとも70%減少させ、より好ましくは、前記免疫エフェクター細胞は、腫瘍を少なくとも80%減少させることを特徴とする
請求項19に記載の用途。 - 医薬組成物であって、
前記医薬組成物は、
請求項1~13のいずれか1項に記載の免疫応答細胞、および
薬学的に許容されるベクターまたは賦形剤を含むことを特徴とする、前記医薬組成物。 - キットであって、
請求項1~13のいずれか1項に記載の免疫応答細胞、および
前記免疫応答細胞を個体に投与する方法を指導する取扱説明書を含むことを特徴とする、前記キット。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/120938 WO2020118634A1 (zh) | 2018-12-13 | 2018-12-13 | 靶向gpc3的免疫效应细胞及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022512450A true JP2022512450A (ja) | 2022-02-03 |
Family
ID=71075860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021534233A Pending JP2022512450A (ja) | 2018-12-13 | 2018-12-13 | Gpc3を標的とする免疫エフェクター細胞およびその応用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220056408A1 (ja) |
EP (1) | EP3907280A4 (ja) |
JP (1) | JP2022512450A (ja) |
WO (1) | WO2020118634A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021259334A1 (zh) * | 2020-06-24 | 2021-12-30 | 南京博望医药科技有限公司 | 自我调节型嵌合抗原受体及其在肿瘤免疫中的应用 |
CN117545771A (zh) | 2021-04-08 | 2024-02-09 | 克莱格医学有限公司 | 细胞免疫治疗的应用 |
WO2022266396A1 (en) * | 2021-06-16 | 2022-12-22 | Senti Biosciences, Inc. | Armed chimeric receptors and methods of use thereof |
WO2023246574A1 (zh) * | 2022-06-24 | 2023-12-28 | 四川科伦博泰生物医药股份有限公司 | 靶向gpc3的抗体及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016523518A (ja) * | 2013-05-08 | 2016-08-12 | 科済生物医薬(上海)有限公司 | Gpc3キメラ抗原受容体蛋白質をコードする核酸及びgpc3キメラ抗原受容体蛋白質を発現するtリンパ球 |
US20180201902A1 (en) * | 2014-12-04 | 2018-07-19 | Carsgen Therapeutics Ltd | Gpc3 and asgpr1 double-targeted transgenic immune effector cell and use thereof |
JP2018522564A (ja) * | 2015-08-03 | 2018-08-16 | カースゲン セラピューティクス リミテッドCarsgen Therapeutics Limited | 抗グリピカン3抗体およびその使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017186121A1 (zh) * | 2016-04-26 | 2017-11-02 | 科济生物医药(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
CN109468279A (zh) * | 2017-09-08 | 2019-03-15 | 科济生物医药(上海)有限公司 | 靶向gpc3的免疫效应细胞及其应用 |
JP2021512875A (ja) * | 2018-02-02 | 2021-05-20 | カースゲン セラピューティクス カンパニー リミテッドCarsgen Therapeutics Co., Ltd. | 細胞免疫療法の組み合わせ |
-
2018
- 2018-12-13 US US17/413,892 patent/US20220056408A1/en active Pending
- 2018-12-13 EP EP18943085.3A patent/EP3907280A4/en not_active Withdrawn
- 2018-12-13 JP JP2021534233A patent/JP2022512450A/ja active Pending
- 2018-12-13 WO PCT/CN2018/120938 patent/WO2020118634A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016523518A (ja) * | 2013-05-08 | 2016-08-12 | 科済生物医薬(上海)有限公司 | Gpc3キメラ抗原受容体蛋白質をコードする核酸及びgpc3キメラ抗原受容体蛋白質を発現するtリンパ球 |
US20180201902A1 (en) * | 2014-12-04 | 2018-07-19 | Carsgen Therapeutics Ltd | Gpc3 and asgpr1 double-targeted transgenic immune effector cell and use thereof |
JP2018522564A (ja) * | 2015-08-03 | 2018-08-16 | カースゲン セラピューティクス リミテッドCarsgen Therapeutics Limited | 抗グリピカン3抗体およびその使用 |
Non-Patent Citations (1)
Title |
---|
TUMOR, vol. 38, JPN6022029289, June 2018 (2018-06-01), pages 631 - 642, ISSN: 0004991646 * |
Also Published As
Publication number | Publication date |
---|---|
EP3907280A1 (en) | 2021-11-10 |
US20220056408A1 (en) | 2022-02-24 |
WO2020118634A1 (zh) | 2020-06-18 |
EP3907280A4 (en) | 2022-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7008350B2 (ja) | Car発現ベクター及びcar発現t細胞 | |
US20240141041A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF | |
EP3680338A1 (en) | Genetically engineered t cell and application thereof | |
JP2023029373A (ja) | キメラ抗体受容体(CARs)の組成物およびその使用方法 | |
JP2022512450A (ja) | Gpc3を標的とする免疫エフェクター細胞およびその応用 | |
JP2023053328A (ja) | ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 | |
TW202140790A (zh) | 病毒載體轉導細胞的方法 | |
US20240009310A1 (en) | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 | |
JP2024509917A (ja) | 腫瘍溶解性ウイルスによる直交性il-2の送達を用いた、固形腫瘍におけるt細胞の選択的刺激方法 | |
JP2023540023A (ja) | Ceaを認識するキメラ抗原受容体(car)発現細胞 | |
US20240002800A1 (en) | Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy | |
WO2023076523A1 (en) | Chimeric adaptor polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210825 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20211209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211209 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220713 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230216 |